Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, Ionis Pharmaceuticals, Inc. (IONS) has a Wall Street consensus price target of $89.13, based on estimates from 32 covering analysts. With the stock currently trading at $81.15, this represents a potential upside of +9.8%. The company has a market capitalization of $13.25B.
Analyst price targets range from a low of $65.00 to a high of $103.00, representing a 43% spread in expectations. The median target of $95.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 20 analysts rating the stock as a Buy or Strong Buy,12 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, IONS trades at a trailing P/E of -34.1x. Analysts expect EPS to grow -60.7% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how IONS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus price target for IONS is $89.13, close to the current price of $81.15 (9.8% implied move). Based on 32 analyst estimates, the stock appears fairly valued near current levels.
IONS has a consensus rating of "Buy" based on 32 Wall Street analysts. The rating breakdown is predominantly bullish, with 20 Buy/Strong Buy ratings. The consensus 12-month price target of $89.13 implies 9.8% upside from current levels.
IONS's current price is $81.15 with a consensus target of $89.13 (9.8% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $103 for IONS, while the most conservative target is $65. The consensus of $89.13 represents the median expectation. These targets typically reflect 12-month expectations.
IONS is heavily covered by Wall Street, with 32 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 19 have Buy ratings, 12 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month IONS stock forecast based on 32 Wall Street analysts shows a consensus price target of $89.13, with estimates ranging from $65 (bear case) to $103 (bull case). The median consensus rating is "Buy".
IONS appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $89.13 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
IONS analyst price targets range from $65 to $103, a 43% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $89.13 consensus represents the middle ground.